BRIEF-Aim Immunotech Reports Year-End Positive Phase 2 Interim Progress For Ampligen® (Rintatolimod) Plus Astrazeneca’S Imfinzi® (Durvalumab) In Pancreatic Cancer

Reuters
Feb 05
BRIEF-Aim Immunotech Reports Year-End Positive Phase 2 Interim Progress For Ampligen® (Rintatolimod) Plus Astrazeneca’S Imfinzi® (Durvalumab) In Pancreatic Cancer

Feb 5 (Reuters) - AIM ImmunoTech Inc AIM.A:

  • AIM IMMUNOTECH REPORTS POSITIVE YEAR-END INTERIM CLINICAL PROGRESS FROM PHASE 2 STUDY EVALUATING AMPLIGEN® (RINTATOLIMOD) IN COMBINATION WITH ASTRAZENECA’S IMFINZI® (DURVALUMAB) FOR THE TREATMENT OF PANCREATIC CANCER

Source text: ID:nGNX5VD198

Further company coverage: AIM.A

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10